FDA Panels Favor Advair, Symbicort Over Single-Entity LABA Products For Asthma
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency must consider whether to change labeling, institute REMS or withdraw the indications for Serevent and Foradil, OND's Jenkins says.
You may also be interested in...
Clinical Trials Or Observational Studies For Asthma? FDA Advisory Panels Can't Agree
Whether randomized controlled clinical trials or observational studies are best for measuring the risks of long acting beta-2 adrenergic agonists remains unresolved after a two-day FDA advisory committee meeting
Clinical Trials Or Observational Studies For Asthma? FDA Advisory Panels Can't Agree
Whether randomized controlled clinical trials or observational studies are best for measuring the risks of long acting beta-2 adrenergic agonists remains unresolved after a two-day FDA advisory committee meeting
Clinical Trials Or Observational Studies for Asthma? FDA Advisory Panels Can't Agree
FDA wants to gather long-term safety data in long acting beta-2 adrenergic agonist asthma drugs.